retatrutide clinical trials efficacy Retatrutide—A Game Changer in Obesity Pharmacotherapy Lilly's triple agonist, retatrutide, delivered

Specifically, this study compares the phenotypic consequences of GLP-1 RA prescription with those of other second-line anti-diabetes therapies, namely sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i)

15 Jul GLP-1 Face: Why Weight Loss Can Change Facial Volume and Skin Laxity GLP-1 weight loss has changed the way many patients view obesity treatment, body shape and metabolic health

Phase 3: peak effect (weeks 20 to 28) Heart rate effects peak around week 24 in the clinical data

The specific hour matters less than your ability to repeat it reliably

Let it sit for a moment and give it another gentle swirl

But something about the triple-action mechanism made sense to me